Definitive Contract 75F40119C10127
Award Date
9/26/19
Potential Completion Date
9/29/21
Potential Value
$288K
Federal Agency
Food and Drug Administration
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Exton, PA 19341, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
34
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm-fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), part of the U.S. Department of Health and Human Services (HHS), to Pharmaron (Exton) Lab Services LLC, doing business as Absorption Systems. The $146,630 contract is for the characterization of the sponsor's test articles via metabolic stability, CYP phenotyping, and in vitro metabolism studies. The contract has no set-aside designation and the work is to be completed by March...
Pharmaron (San Diego) Lab Services LLC was awarded a two-year, firm fixed price delivery order valued at one million, five hundred seventy-four thousand, seventy dollars and thirty-six cents ($1,574,070.36) by the Department of Health and Human Services' Food and Drug Administration (FDA). Under the contract, Pharmaron will provide pharmacokinetic and pharmacodynamic studies of topically administered ophthalmic intraocular pressure drug formulations in rabbits to support the FDA's evaluation and...
The Department of Health and Human Services National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases awarded a $17,267 purchase order to Pharmaron (Exton) Lab Services LLC, doing business as Absorption Systems, for testing services. The firm fixed price contract has a period of performance from August 23, 2016 to September 30, 2016 for work to be conducted in Bethesda, Maryland. No additional details were provided regarding the scope of testing services...
This federal contract award was issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a global contract research organization. The $87,805.00 firm fixed price contract was awarded as a delivery order under the NIH Bioanalysis Testing Services 2015-2020 master contract vehicle. Under this contract, Pharmaron conducted various drug development activities for NCATS, including...
This firm fixed-price purchase order was awarded by the Department of Health and Human Services' (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a minority-owned for-profit organization, to conduct testing of compounds for the blocking of cardiac ion channels. The period of performance is from August 7, 2020 to December 31, 2021, with a potential value of $24,795.00. The work is being performed in Louisville, Kentucky....
This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Pharmaron, Inc.'s Phamaron Inc. Division. The contract, valued at $23,040.00, is for a pharmacokinetics assessment of eight novel compounds in mice and rats. Pharmaron is a global contract research organization (CRO) that specializes in preclinical research services, including pharmacokinetics assessments, toxicity...
This federal contract award to Pharmaron, Inc., a Minority Owned Business and For Profit Organization, was issued by the U.S. Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS). The contract, valued at $117,930.00, is a Firm Fixed Price Purchase Order to evaluate NNMT inhibitors in metabolic disorders. Pharmaron, a global contract research organization, will conduct various drug development activities...
The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services (HHS), has awarded a $124,200.00 firm fixed-price purchase order contract to Pharmaron, Inc., a minority-owned business based in China, to evaluate the pharmacokinetics of compounds from dystonia in mice, dogs, and rats. This sole-source contract, awarded under simplified acquisition procedures, will require Pharmaron to provide consistency and...
The National Institutes of Health's National Center for Advancing Translational Sciences awarded a $39,060 firm fixed price purchase order to Pharmaron, Inc. to evaluate absorption, distribution, metabolism, and excretion of compounds from an NIH dystonia research project. Per the sole source solicitation, Pharmaron will leverage its unique experience with the class of compounds to provide consistency and reproducibility in the evaluation process, compare new analogs to previous ones in the same...
This is a firm fixed-price delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Pharmaron, Inc. for $149,520.00. The award is under the NIH Bioanalysis Testing Services 2015-2020 indefinite delivery/indefinite quantity (IDIQ) contract vehicle. Pharmaron, a minority-owned, for-profit contract research organization (CRO), will provide pharmacokinetics assessments, toxicity studies, and ion channel testing...